Biotech investment landscape: Strategies and forecasts for 20248 days agoJim CornallBy Jim Cornallmore_vert
Seven biotech companies climbing their way up in Colorado11 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
6 biotechnology universities in the USA developing young talent15 days agoWillow Shah-nevilleBy Willow Shah-nevillemore_vert
What you need to know to become a research assistant18 hours agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
10 of the most expensive drugs in biopharma2 days agoWillow Shah-nevilleBy Willow Shah-nevillemore_vert
Tackling malaria: What are the new treatments?2 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
How to overcome rare disease clinical trial challenges?4 days agoUte BoronowskyBy Ute Boronowskymore_vert
The biggest private biotech investments in March 20245 days agoWillow Shah-nevilleBy Willow Shah-nevillemore_vert
5 RNA editing companies you should know about8 days agoWillow Shah-nevilleBy Willow Shah-nevillemore_vert
Small but mighty: The role of small-molecule drugs in disease treatment10 days agoWillow Shah-nevilleBy Willow Shah-nevillemore_vert
Eight biotech companies you should know about in Austria18 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
Seven groundbreaking mRNA companies to look out for16 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
Does the FDA need to tighten its grip on drug trials in the U.S.?12 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
Doloromics: Revolutionizing chronic pain treatment with omics15 days agoJim CornallBy Jim Cornallmore_vert
Colossal Biosciences aims to revive the woolly mammoth by 202819 days agoJim CornallBy Jim Cornallmore_vert
Tissue engineering: Six key companies to put on your radar23 days agoJules AdamBy Jules Adammore_vert
Are new treatments for multiple sclerosis on the horizon?Mar 27Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Large molecule manufacturing: Challenges and winning strategiesMar 26Alexander BurikBy Alexander Burikmore_vert
Amycretin: Novo Nordisk's new rival to Wegovy in obesity treatmentMar 27Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Eight CAR-T cell therapy companies you should know aboutMar 21Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Are molecular glues the key to undruggable targets?Mar 26Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Advances in Rett syndrome treatment: the rise of gene therapyMar 14Roohi Mariam PeterBy Roohi Mariam Petermore_vert
6 biotechnology universities in the UK leading the way for future talentMar 22Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Terran Biosciences: Redefining neuro treatment with psychedelicsMar 25Jim CornallBy Jim Cornallmore_vert
Programmable genomic integration: the zenith of genomic medicineMar 1Jim CornallBy Jim Cornallmore_vert
New non-opioid pain medication: what is in the pipeline?Feb 29Willow Shah-nevilleBy Willow Shah-nevillemore_vert
7 oncolytic virus companies revolutionizing cancer treatmentMar 18Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Beyond fundraising: how do venture capitals build early-stage biotechs?Feb 28Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Eight biotechnology universities in Germany nurturing innovatorsMar 8Jules AdamBy Jules Adammore_vert
Is Novo Nordisk's Catalent deal shaping a new era in biopharma?Feb 27Jules AdamBy Jules Adammore_vert
6 pediatric companies revolutionizing children's careFeb 29Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Protein inhibitors: cracking the code of disease mechanismsMar 14Ute BoronowskyBy Ute Boronowskymore_vert
Greening the lab: Strategies for sustainable drug developmentMar 18Alexander BurikBy Alexander Burikmore_vert
Precision neuromedicine: A new dawn for neurological disordersFeb 23Jim CornallBy Jim Cornallmore_vert
This new approach could revolutionize knee osteoarthritis treatmentFeb 2Jim CornallBy Jim Cornallmore_vert
Biogen: how is the biotech pivoting from a failed Alzheimer's drug?Feb 15Jules AdamBy Jules Adammore_vert